Patents by Inventor Qiangang Zheng

Qiangang Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10844079
    Abstract: Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: November 24, 2020
    Assignee: Etern Biopharma (Shanghai) Co., Ltd.
    Inventors: Qiangang Zheng, Ming Xu, Qinglong Zeng, Jing Li, Hao Zhuge
  • Publication number: 20200317695
    Abstract: Provided is a compound of formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, isotopic substituent, polymorph, prodrug, or metabolite thereof. Also provided is a method for preparing the compound of formula I. The compound of formula I has higher inhibitory activity against SHP2, and thus can be used to prevent or treat a disease related to SHP2.
    Type: Application
    Filed: June 22, 2020
    Publication date: October 8, 2020
    Inventors: Qiangang Zheng, Ming Xu, Qinglong Zeng, Jing Li, Hao Zhuge
  • Patent number: 10682352
    Abstract: Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: June 16, 2020
    Assignees: SHANGHAI HAIHE PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Lei Jiang, Meiyu Geng, Qiangang Zheng, Min Huang, Huixin Wan, Shuai Tang, Xianlei Fu, Xiaojing Lan, Jianhua Cao, Feifei Liu, Jian Ding
  • Patent number: 10604502
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, and R5 are as defined herein.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: March 31, 2020
    Assignee: Novartis AG
    Inventors: Lei Du-Cuny, Qitao Xiao, Guoliang Xun, Qiangang Zheng
  • Patent number: 10590079
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, R5, and R6 are as defined herein.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Novartis AG
    Inventors: Lei Du-Cuny, Feng He, Qitao Xiao, Guoliang Xun, Qiangang Zheng
  • Publication number: 20190298715
    Abstract: Provided herein is the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
    Type: Application
    Filed: September 29, 2017
    Publication date: October 3, 2019
    Inventors: Gregory Motz, Konstantinos John Mavrakias, Jinbiao Liu, Lei Liu, Qiangang Zheng, Guoliang Xun, Qitao Xiao
  • Publication number: 20190119200
    Abstract: Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 25, 2019
    Inventors: Lawrence A. Black, William H. Bunnelle, Da Chen, Bruce Clapham, David A. Degoey, Xiangjun Deng, Liqiang Fu, Lisa A. Hazelwood, Linglong Kong, Qingyu Lang, Chih-Hung Lee, Mingfeng Li, Greta L. Lundgaard, Meena V. Patel, Ruihong Tao, Lin Zhang, Qingwei Zhang, Qiangang Zheng, Wei Zhu
  • Publication number: 20190111056
    Abstract: Provided in the present invention are a compound having the effects of preventing and treating diseases related to IDH mutation, and a preparation method and use thereof.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 18, 2019
    Inventors: Lei JIANG, Meiyu GENG, Qiangang ZHENG, Min HUANG, Huixin WAN, Shuai TANG, Xianlei FU, Xiaojing LAN, Jianhua CAO, Feifei LIU, Jian DING
  • Publication number: 20190092724
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, R5, and R6 are as defined herein.
    Type: Application
    Filed: February 28, 2017
    Publication date: March 28, 2019
    Inventors: Lei DU-CUNY, Feng HE, Qitao XIAO, Guoliang XUN, Qiangang ZHENG
  • Publication number: 20190023684
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1)-mediated diseases or disorders: wherein R1, R2, R3, R4, and R5 are as defined herein.
    Type: Application
    Filed: June 19, 2018
    Publication date: January 24, 2019
    Inventors: Lei DU-CUNY, Qitao XIAO, Guoliang XUN, Qiangang ZHENG
  • Publication number: 20190000880
    Abstract: Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.
    Type: Application
    Filed: December 30, 2016
    Publication date: January 3, 2019
    Inventors: Gregory Motz, Konstantinos John Mavrakias, Jinbiao Liu, Lei Liu, Qiangang Zheng, Guoliang Xun, Qitao Xiao